Cargando…
Current and Emerging Role of Monoclonal Antibody-Based First-Line Treatment in Advanced Gastro-Esophageal and Gastric Cancer
Gastric cancer is the fifth most common malignancy worldwide and one of the main causes of cancer-related death. While surgical treatment is the only curative option for early disease, many have inoperable or advanced disease at diagnosis. Treatment in this case would be a combination of chemotherap...
Autores principales: | Désilets, Audrey, Elkhoury, Reem, Gebai, Ahmad, Tehfe, Mustapha |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10605724/ https://www.ncbi.nlm.nih.gov/pubmed/37887572 http://dx.doi.org/10.3390/curroncol30100672 |
Ejemplares similares
-
Successes and failures of angiogenesis blockade in gastric and gastro-esophageal junction adenocarcinoma
por: Salati, Massimiliano, et al.
Publicado: (2022) -
Gastro-Esophageal Reflux in Children
por: Rybak, Anna, et al.
Publicado: (2017) -
Current Role of Immunotherapy in Gastric, Esophageal and Gastro-Esophageal Junction Cancers—A Report from the Western Canadian Gastrointestinal Cancer Consensus Conference
por: Mulder, Karen, et al.
Publicado: (2022) -
Minimum biopsy set for HER2 evaluation in gastric and gastro-esophageal junction cancer
por: Gullo, Irene, et al.
Publicado: (2015) -
Clinical role of ramucirumab alone or in combination with paclitaxel for gastric and gastro-esophageal junction adenocarcinoma
por: Davidson, Michael, et al.
Publicado: (2016)